SEARCH:   Advanced

Blood, 15 April 2006, Vol. 107, No. 8, pp. 3074-3080. Prepublished online as a Blood First Edition Paper on December 20, 2005; DOI 10.1182/blood-2005-09-3907. This Article Full Text (PDF) All Versions of this Article: 2005-09-3907v1 107/8/3074    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Couriel, D. R Articles by Donato, M. Search for Related Content PubMed PubMed Citation Articles by Couriel, D. R Articles by Donato, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 30, 2005 Accepted December 5, 2005 Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD Daniel R Couriel*, Chitra Hosing, Rima Saliba, Elizabeth J Shpall, Paolo Anderlini, Beverly Rhodes, Veronica Smith, Issa Khouri, Sergio Giralt, Marcos de Lima, Yvonnne Hsu, Shubhra Ghosh, Joyce Neumann, Borje Andersson, Muzzafar Qazilbash, Sharon Hymes, Stella Kim, Richard Champlin, and Michele Donato Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA * Corresponding author; email: DCOURIEL{at}MDANDERSON.ORG. Chronic graft-versus-host disease (GVHD) is a major limitation of successful allogeneic hematopoietic stem cell transplantation (HSCT). Extracorporeal photochemotherapy (ECP) has been tested extensively in small cohorts of patients with chronic GVHD. In this study, we retrospectively evaluated 71 patients with severe chronic GVHD treated with ECP. Response rate was 61% (n= 43), and 14 patients had complete responses. The best responses were observed in skin, liver, oral mucosa and eye. Factors affecting outcomes were assessed in the less heavily pretreated subgroup (n= 63). Thrombocytopenia was associated with a lower response rate (p= 0.04) and there was a trend towards a higher response rate in de novo chronic GVHD. At 6 months, a total of 27/39 (69%) patients who were alive continued to have a sustained response (CR 4/39, 10% and PR 23/39, 59%). The cumulative incidence of steroid discontinuation at 1 year was 22%. The overall survival since initiation of therapy was 53 % at 1 year. Response to ECP and platelet count at initiation of therapy were the strongest predictors of NRM on univariate analysis. Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-M. Dubernard, B. Lengele, E. Morelon, S. Testelin, L. Badet, C. Moure, J.-L. Beziat, S. Dakpe, J. Kanitakis, C. D'Hauthuille, et al. Outcomes 18 Months after the First Human Partial Face Transplantation N. Engl. J. Med., December 13, 2007; 357(24): 2451 - 2460. [Abstract] [Full Text] [PDF] D. A. Jacobsohn, A. R. Chen, M. Zahurak, S. Piantadosi, V. Anders, J. Bolanos-Meade, M. Higman, J. Margolis, M. Kaup, and G. B. Vogelsang Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease J. Clin. Oncol., September 20, 2007; 25(27): 4255 - 4261. [Abstract] [Full Text] [PDF] H. J. Deeg How I treat refractory acute GVHD Blood, May 15, 2007; 109(10): 4119 - 4126. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020